Cytiva_APR21_EarlyProcessDevDecisions - Cover3

EARLY PROCESS DEVELOPMENT DECISIONS PAY OFF FOR CELL AND GENE THERAPIES

lifecycle of a product, but the high cost of labour

in the development of non-viral genetic engi-

and need for reproducibility within manufac-

neering solutions, such as Avectas, Kytopen, SQZ

turing functions really drive the need, Smith says.

Biotech, that are generating novel methods to
add or remove genetic material to cells, therefore

FUTURE

enhancing their function. "
Demand for more advanced hardware is also a

HCATS' facility also houses a development laboratory. The idea is to help customers improve

factor Smith says, explaining " There is a drive for

processes and integrate novel manufacturing tech-

suppliers of software solutions to start spreading

niques as the sector develops, notes Heathman.

their reach. We see software companies now

Embracing innovation is also critical for cell

increasing capabilities to not focus on one facet

and gene therapy developers, according to

but incorporate adjoining needs, like an MES

Smith, who says techniques and technologies

company offering LIMS or Track and Trace, with

are advancing quickly. " There is a vast increase

companies like Werum, L7 and Vineti. "

n

Life science online courses
Browse our learning courses and grow your skills.

Browse
courses

From Lab To Life
CCRM is a catalyst for commercializing regenerative medicinebased technologies and cell and gene therapies. We enable
product development through the unique translational platforms
that address the key bottlenecks
in regenerative medicine
Visit the
commercialization.

webpage

GENengnews.com

| 37


https://www.cytivalifesciences.com/en/se/education/online-learning/courses https://www.ccrm.ca/ http://www.GENengnews.com

Cytiva_APR21_EarlyProcessDevDecisions

Table of Contents for the Digital Edition of Cytiva_APR21_EarlyProcessDevDecisions

Contents
Cytiva_APR21_EarlyProcessDevDecisions - Cover1
Cytiva_APR21_EarlyProcessDevDecisions - Cover2
Cytiva_APR21_EarlyProcessDevDecisions - Contents
Cytiva_APR21_EarlyProcessDevDecisions - 4
Cytiva_APR21_EarlyProcessDevDecisions - 5
Cytiva_APR21_EarlyProcessDevDecisions - 6
Cytiva_APR21_EarlyProcessDevDecisions - 7
Cytiva_APR21_EarlyProcessDevDecisions - 8
Cytiva_APR21_EarlyProcessDevDecisions - 9
Cytiva_APR21_EarlyProcessDevDecisions - 10
Cytiva_APR21_EarlyProcessDevDecisions - 11
Cytiva_APR21_EarlyProcessDevDecisions - 12
Cytiva_APR21_EarlyProcessDevDecisions - 13
Cytiva_APR21_EarlyProcessDevDecisions - 14
Cytiva_APR21_EarlyProcessDevDecisions - 15
Cytiva_APR21_EarlyProcessDevDecisions - 16
Cytiva_APR21_EarlyProcessDevDecisions - 17
Cytiva_APR21_EarlyProcessDevDecisions - 18
Cytiva_APR21_EarlyProcessDevDecisions - 19
Cytiva_APR21_EarlyProcessDevDecisions - 20
Cytiva_APR21_EarlyProcessDevDecisions - 21
Cytiva_APR21_EarlyProcessDevDecisions - 22
Cytiva_APR21_EarlyProcessDevDecisions - 23
Cytiva_APR21_EarlyProcessDevDecisions - 24
Cytiva_APR21_EarlyProcessDevDecisions - 25
Cytiva_APR21_EarlyProcessDevDecisions - 26
Cytiva_APR21_EarlyProcessDevDecisions - 27
Cytiva_APR21_EarlyProcessDevDecisions - 28
Cytiva_APR21_EarlyProcessDevDecisions - 29
Cytiva_APR21_EarlyProcessDevDecisions - 30
Cytiva_APR21_EarlyProcessDevDecisions - 31
Cytiva_APR21_EarlyProcessDevDecisions - 32
Cytiva_APR21_EarlyProcessDevDecisions - 33
Cytiva_APR21_EarlyProcessDevDecisions - 34
Cytiva_APR21_EarlyProcessDevDecisions - 35
Cytiva_APR21_EarlyProcessDevDecisions - 36
Cytiva_APR21_EarlyProcessDevDecisions - Cover3
Cytiva_APR21_EarlyProcessDevDecisions - Cover4
https://www.nxtbookmedia.com